Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WDB coco CoTSE:7079 -1.15%72 EPS without NRI is 円282.47 as of Mar. 2026. GuruFocus rates TSE:7079 with a GF Score™ of 72/100 and a GF Value™ of 円3,465.36 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 510 Healthcare Providers & Services companies, WDB coco Co ranks worse than 70.39% on this metric.
WDB coco Co's earnings per share without non-recurring items for the
six
months ended in Mar. 2026 was 円166.41.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 円282.47.
During the past 12 months, WDB coco Co's average earnings per share (NRI) Growth Rate was -25.60% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was -3.00% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 12.50% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for WDB coco Co's EPS without NRI or its related term are showing as below:
TSE:7079'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -3 Med: 25.05 Max: 31.7
Current: -3
During the past 9 years, WDB coco Co's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 31.70% per year. The lowest was -3.00% per year. And the median was 25.05% per year.
TSE:7079's 3-Year EPS without NRI Growth Rate is ranked worse than 70.39% of 510
companies
in the Healthcare Providers & Services industry
Industry Median: 11.55
vs TSE:7079: -3.00
WDB coco Co's EPS (Diluted) for the
six
months ended in Mar. 2026 was 円166.41.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円282.47.
WDB coco Co's EPS (Basic) for the
six
months ended in Mar. 2026 was 円166.41.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was 円282.47.
WDB coco Co (TSE:7079) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
WDB coco Co EPS without NRI Related Terms
WDB coco Co EPS without NRI Historical Data
* Premium members only.
The historical data trend for WDB coco Co's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7079 vs VEEV, BTSG, TEM: EPS without NRI Comparison
For the Health Information Services subindustry, WDB coco Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WDB coco Co PE Ratio without NRI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, WDB coco Co's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where WDB coco Co's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円282.47
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WDB coco Co (TSE:7079) has a EPS without NRI of 円282.47 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on WDB coco Co and its competitors. According to the industry distribution chart, WDB coco Co ranks #359 out of 510 companies in the Healthcare Providers & Services industry, placing it in the top 70.4%.
Is WDB coco Co's EPS without NRI too high?
WDB coco Co's current EPS without NRI is 円282.47. Based on the distribution chart, WDB coco Co ranks #359 out of 510 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, WDB coco Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WDB coco Co's EPS without NRI compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, WDB coco Co ranks #359 out of 510 companies for EPS without NRI. This places WDB coco Co in the lower half of its industry. The industry median EPS without NRI is 11.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Healthcare Providers & Services company?
The median EPS without NRI among Healthcare Providers & Services companies is 11.55, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on WDB coco Co and its competitors. For the Healthcare Providers & Services industry, the median EPS without NRI is 11.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WDB coco Co's current EPS without NRI is 円282.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WDB coco Co stock overvalued right now?
Based on GuruFocus' analysis, WDB coco Co (TSE:7079) is currently considered Modestly Undervalued. The stock's GF Value™ is 円3,465.36, compared to a current price of 円2,580.00 — trading 25.5% below its estimated fair value. The current EPS without NRI is 円282.47. WDB coco Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For WDB coco Co (TSE:7079), the current EPS without NRI is 円282.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WDB coco Co (TSE:7079) Overvalued in 2026?
Based on GuruFocus' analysis, WDB coco Co stock appears to be undervalued.
The current stock price of 円2,580.00 is trading 25.5% below its estimated GF Value™ of 円3,465.36.
GuruFocus considers WDB coco Co to be Modestly Undervalued.
Key valuation signals for TSE:7079:
EPS without NRI: 円282.47
GF Value™: 円3,465.36 vs. price of 円2,580.00 (25.5% below fair value)
No single metric tells the full story. See the TSE:7079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WDB coco Co Ltd is a provider of safety information management for the development of pharmaceuticals and medical devices. Its services include business related to safety information management, preparation of materials related to regulatory application, QC-related work, PMS facility contract support related work, clinical research support/monitoring, and temporary staffing. The company provides Contract Research Organization services for all new drug developments, such as monitoring, safety information, data management, and statistical analysis. It provides support for the development of generic drugs, such as bioequivalence studies and biosimilars, clinical research, and physician-led clinical trials.
72GF Score
Get the complete analysis for TSE:7079
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7079 has been successfully added to your 
